Tetrahydrobiopterin in the Treatment of Infantile Hypertrophic Pyloric Stenosis

Christian P. Braegger , Marcus Schwöbel , Jakob von Känel , Ernst R. Werner , Beat Thöny , Nenad Blau
{"title":"Tetrahydrobiopterin in the Treatment of Infantile Hypertrophic Pyloric Stenosis","authors":"Christian P. Braegger ,&nbsp;Marcus Schwöbel ,&nbsp;Jakob von Känel ,&nbsp;Ernst R. Werner ,&nbsp;Beat Thöny ,&nbsp;Nenad Blau","doi":"10.1006/bmme.1997.2628","DOIUrl":null,"url":null,"abstract":"<div><p>Evidence is emerging that reduced nitric oxide production may be involved in the pathogenesis of hypertrophic pyloric stenosis. Nitric oxide synthase (NOS) requires tetrahydrobiopterin (BH<sub>4</sub>) for activity. Four infants with hypertrophic pyloric stenosis were treated with oral BH<sub>4</sub>(10 mg/kg/day) for 2.5 days. Although plasma total biopterin increased significantly at 3, 27, and 51 h after BH<sub>4</sub>administration, there was no effect on the production of plasma cGMP, nitrite, nitrate, or citrulline. Ultrasound investigations before and after the ingestion of BH<sub>4</sub>revealed no changes in the hypertrophic pyloric stenosis. We conclude that oral BH<sub>4</sub>, in the dose utilized in our investigations, does not modify the cause of hypertrophic pyloric stenosis, presumably because it did not restore nitric oxide production in the nonadrenergic noncholinergic nerves of the enteric nervous system.</p></div>","PeriodicalId":8837,"journal":{"name":"Biochemical and molecular medicine","volume":"62 1","pages":"Pages 101-105"},"PeriodicalIF":0.0000,"publicationDate":"1997-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1006/bmme.1997.2628","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical and molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1077315097926284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Evidence is emerging that reduced nitric oxide production may be involved in the pathogenesis of hypertrophic pyloric stenosis. Nitric oxide synthase (NOS) requires tetrahydrobiopterin (BH4) for activity. Four infants with hypertrophic pyloric stenosis were treated with oral BH4(10 mg/kg/day) for 2.5 days. Although plasma total biopterin increased significantly at 3, 27, and 51 h after BH4administration, there was no effect on the production of plasma cGMP, nitrite, nitrate, or citrulline. Ultrasound investigations before and after the ingestion of BH4revealed no changes in the hypertrophic pyloric stenosis. We conclude that oral BH4, in the dose utilized in our investigations, does not modify the cause of hypertrophic pyloric stenosis, presumably because it did not restore nitric oxide production in the nonadrenergic noncholinergic nerves of the enteric nervous system.

四氢生物蝶呤治疗婴儿肥厚性幽门狭窄
越来越多的证据表明,一氧化氮的产生减少可能与肥厚性幽门狭窄的发病机制有关。一氧化氮合酶(NOS)的活性需要四氢生物蝶呤(BH4)。4例肥厚性幽门狭窄患儿口服BH4(10 mg/kg/天)治疗2.5天。虽然bh4给药后3、27和51小时血浆总生物terin显著增加,但对血浆cGMP、亚硝酸盐、硝酸盐或瓜氨酸的产生没有影响。摄入bh4前后超声检查显示肥厚性幽门狭窄无变化。我们得出结论,口服BH4,在我们的研究中使用的剂量,并不能改变肥厚性幽门狭窄的原因,可能是因为它不能恢复肠道神经系统的非肾上腺素能非胆碱能神经中一氧化氮的产生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信